KENNA RASIKLAL

“These SAR changes refer to GN-26 and GN-27 applications and take effect on the 1st of April, 2022.

.”

Kenna Rasiklal
Principal Consultant
Asia Actual Singapore

Come grow with us in the US in Thailand in China in Korea in the Philippines in Taiwan in Hong Kong

Sources and Links

Singapore’s HSA Issues New Guidance on Special Access Routes (SAR)

Published on: March 30th, 2022

Singapore’s Health Science Authority (HSA) recently held a zoom conference call outlining the new requirements for the Special Authorization Routes GN-26 and GN-27 taking effect on April 1, 2022. Class C and D devices being used by public health institutions (PHIs) will now need to complete an additional clinical justification form. Changed are being implemented to continue improving patient safety in Singapore. The new Special Authorization Routes (SAR) guidance can be found here and hospitals have already been made aware of the new requirements.

While the HSA has not released official review times, it was noted during the zoom meeting that class C and D GN-26 and GN-27 applications will take longer than class B (14 working days). For urgent applications, the HSA is advising license holders to split their GN applications according to the risk class to expedite their review.

What to Do with Stock Covered by an Expired GN-27

The HSA has also clarified that if a GN-27 has expired, the supply and USE of the devices is no longer allowed and a new application will need to be submitted for the remaining stock.

Special Authorization Routes Available in Singapore

GN-26 applications are for “licensed qualified practitioners to seek approval for the import and supply of unregistered medical devices for use on his patient” while GN-27 applications are for “healthcare facilities licensed under the Private Hospitals and Medical Clinics Act (PHMCA) / Healthcare Services Act (HCSA) to seek approval for the import and supply of unregistered medical devices for use on their patients.”

Current fees can be found here and more information on the regulatory process can be found here.

Special Authorization Routes (SAR) Fees and Turnaround Time

Below are the current HSA fees for SARs but it is expected that new fees and timelines will be issued for the new class C and D routes in the near future.

Special Access Routes Fees

(SGD)

Turnaround time (in working days)
Import for re-export of unregistered devices $258 14
Unregistered devices for non-clinical purposes $258 14
Unregistered devices requested by qualified practitioners $155 14
Unregistered devices requested by a licensed PHMC $360 14

All fees are in Singapore dollars. S$100 = US$70.5 as of January 2022

Please see our Singapore Medical Device Registration page for more information on registration fees and timelines.

Grow with Us

Asia Actual specializes in helping medical device manufacturers grow their sales in Asia with experienced, bi-lingual commercial and regulatory experts on the ground in Singapore. Contact Asia Actual today if you have questions or need support importing medical products into Singapore.

Blog Posts

China’s NMPA Updates Medical Device Classification Catalogue

China’s National Medical Products Administration (NMPA) maintains a list of all medical device categories called the Medical Device Classification Catalogue. NMPA published a notice on August 17, 2023, that they had released amendments to the Medical Device Classification Catalogue. It’s important for manufacturers to understand these changes as they can significantly impact the cost and time to register medical devices.

Thai FDA Drafting New Guidance for SaMD and AI Device Registration

Thai FDA is drafting new guidelines for AI Regulation. The novel characteristics of artificial intelligence (AI) software cause issues with the medical device registration process in most countries. The Thai Food and Drug Administration (Thai FDA) is working to address this important issue, most recently by hosting a meeting with interested parties on July, 2023, which Asia Actual Thailand employees were invited to attend.

China NMPA Adds 47 Products to Clinical Trial Exemption List

China’s National Medical Products Administration (NMPA) updated its clinical trial exemption list, adding 47 products. The NMPA updates this list every two to three years, with the last amendment in 2021. This brings the total number of clinical trial exempted product categories in China to 1,025.